Serina Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $51.8M
- Price
- $2.04
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 8.7K
About
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Quick stats
Shares outstanding25.4M
Computed float4.5M
Float / shares17.6%
Cash runway (months)7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001708599
AI Summary
AI-generated1/24
minorneutralother
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Serina Therapeutics announced registration is open for a Tribe Public webinar on September 24, 2026, where CEO Steven Ledger will discuss SER-252's clinical progress in advanced Parkinson's disease.
The event is an investor-awareness webinar with Q&A, not a data release; no new clinical or financial results were disclosed.
SER-252 (POZ-apomorphine) is Serina's lead program, a long-acting treatment being developed for advanced Parkinson's disease using its POZ Platform technology.